Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Vaccinology

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Oxford coronavirus vaccine produces strong immune response in older adults

COVID-19 Vaccinology

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

SIMON Says…

Vaccinology

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Children’s pain ‘swept under the carpet for too long’ – Lancet Commission

Neuroimaging Publication Research

The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.

Paul Riley appointed Director of Oxford’s Institute of Developmental and Regenerative Medicine

Immunology

Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.

Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show

COVID-19 Vaccinology

Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.

Enriching Engagement (Round 2) awardees announced

Awards & Appointments Neuromuscular Diseases Public Engagement

The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.

There is now clear data on Covid-19 and children: it should be safe to reopen English schools

Parents & Carers Vaccinology

In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.

Featured publication: Advances in oligonucleotide drug delivery

Neuromuscular Diseases Publication

Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.

Typhoid vaccine project wins Vice-Chancellor award

Awards & Appointments Vaccinology

Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!

New study reveals Oxford coronavirus vaccine produces strong immune response

COVID-19

A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University’s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.

Ebola vaccine approved for use by the European Commission

Vaccinology

The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.

The Duke of Cambridge visits Oxford Vaccine Centre

COVID-19 Vaccinology

The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

COVID-19 Clinical Trials Vaccinology

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.

Alice in Typhoidland wins film trophy

Bristol Science Film Festival awarded the Professional Science Fact Film Prize to "The Adventures of Alice in Typhoidland" co-created by the Oxford Vaccine Group.

Coronavirus: is it safe for children to return to school?

COVID-19 Children's Health General Parents & Carers

Stéphane Paulus and Else Bijker explore the topic in their article for The Conversation.

Oxford COVID-19 vaccine to begin phase II/III human trials

COVID-19 Clinical Trials Vaccinology

Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.

Paediatrics professor honoured by the Academy of Medical Sciences

The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has announced the election of fifty new Fellows, including Professor Matthew Wood from the Department of Paediatrics.

HIV study explains immunological differences between sexes

HIV

How can researching a cohort of infants from KwaZulu-Natal in South Africa help explain differing HIV susceptibility of males and females? Professor Philip Goulder, head of the HIV Research Group, discusses the Baby Cure study.

Load More